Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biricodar. Vertex Pharmaceuticals.

Saibal Dey1

  • 1Department of Biochemistry and Molecular Biology, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine, Bethesda, MD 20814-4799, USA. sdey@usuhs.mil

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary

Vertex is developing biricodar to overcome multidrug resistance in cancer chemotherapy. Phase II trials are underway for breast, ovarian, lung, and prostate cancers, aiming to restore chemotherapy effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.

Biochemistry·2012
Same author

Low concentration of arsenic could induce caspase-3 mediated head kidney macrophage apoptosis with JNK-p38 activation in Clarias batrachus.

Toxicology and applied pharmacology·2009
Same author

Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes.

Planta medica·2007
Same author

Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.

Biochemical pharmacology·2006
Same author

Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).

Biochemical pharmacology·2006
Same author

Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates.

Archives of biochemistry and biophysics·2006

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in tumors significantly limits chemotherapy efficacy.
  • Biricodar is a chemosensitizing agent developed to restore the effectiveness of chemotherapeutic agents.
  • Vertex Pharmaceuticals is the sole developer of biricodar.

Purpose of the Study:

  • To evaluate biricodar as a chemosensitizer in combination with chemotherapy.
  • To assess the potential of biricodar in treating common cancer indications with MDR.

Main Methods:

  • Phase II clinical trials were initiated for biricodar in combination with chemotherapy.
  • Trials target breast, ovarian, soft-tissue sarcomas, small cell lung cancer, and prostate cancer.
  • Patent applications disclose biricodar derivatives for treating MDR tumors.

Main Results:

  • Phase II trials commenced by November 1998 and were ongoing as of January 2002.
  • Vertex terminated an agreement with BioChem Pharma in March 2000, becoming the sole developer.
  • Analyst reports forecast a potential market launch in late 2005 with estimated peak sales of $250 million.

Conclusions:

  • Biricodar shows potential as a chemosensitizing agent to combat multidrug resistance in various cancers.
  • Ongoing clinical trials and patent filings indicate continued development efforts.
  • Market entry is anticipated in the second half of 2005, subject to trial outcomes and regulatory approval.

Related Experiment Videos